Filtered By:
Cancer: Bone Cancers
This page shows you your search results in order of date.
Order by Relevance | Date
Total 366 results found since Jan 2013.
In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy
Cell Death & Disease, Published online: 22 September 2023; doi:10.1038/s41419-023-06159-3In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy
Source: Cell death and disease - September 22, 2023 Category: Internal Medicine Authors: Lingfeng Yu Gentao Fan Qingyan Wang Yan Zhu Hao Zhu Jiang Chang Zhen Wang Shoubin Zhan Xianming Hua Diankun She Jianhao Huang Yicun Wang Jianning Zhao Chen-Yu Zhang Xi Chen Guangxin Zhou Source Type: research
Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy
ConclusionThis study revealed that CPDA/siSTAT3@SCM NPs can target drug delivery by biomimetic multifunctional nanoparticles to treat OS through chemo-gene combined therapy.
Source: Cancer Nanotechnology - June 20, 2023 Category: Cancer & Oncology Source Type: research
The histone acetyltransferase Mof regulates Runx2 and Osterix for osteoblast differentiation
AbstractOsteoblast differentiation is regulated by various transcription factors, signaling molecules, and posttranslational modifiers. The histone acetyltransferase Mof (Kat8) is involved in distinct physiological processes. However, the exact role of Mof in osteoblast differentiation and growth remains unknown. Herein, we demonstrated that Mof expression with histone H4K16 acetylation increased during osteoblast differentiation. Inhibition of Mof by siRNA knockdown or small molecule inhibitor, MG149 which is a potent histone acetyltransferase inhibitor, reduced the expression level and transactivation potential of osteog...
Source: Cell and Tissue Research - May 29, 2023 Category: Cytology Source Type: research
GADD34 activates p53 and may have utility as a marker of atherosclerosis
Front Med (Lausanne). 2023 May 9;10:1128921. doi: 10.3389/fmed.2023.1128921. eCollection 2023.ABSTRACTWe previously identified growth arrest and DNA-damage-inducible gene 34 (GADD34) as a marker of ischemic stroke. In the present study, serum levels of anti-GADD34 antibodies were found to be significantly higher in patients with acute ischemic stroke or chronic kidney disease compared to healthy donors. We then examined the biological function of GADD34 by transfection into U2OS human osteosarcoma and U87 human glioblastoma cells. Knockdown of GADD34 by siRNA resulted in enhanced cell proliferation, which was reversed by c...
Source: Atherosclerosis - May 25, 2023 Category: Cardiology Authors: Go Tomiyoshi Rika Nakamura Natsuko Shinmen Yoichi Yoshida Seiichiro Mine Toshio Machida Katsuro Iwase Yasuo Iwadate Takaki Hiwasa Hideyuki Kuroda Source Type: research
Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition
In this study, we assessed the impact of vitamin D and its receptor (VDR) on NMD-ROS-EMT signaling in in vitro and in vivo osteosarcoma animal models. Initiation of VDR signaling facilitated the enrichment of EMT pathway genes, after which 1,25(OH)2D, the active vitamin D derivative, inhibited the EMT pathway in osteosarcoma subtypes. The ligand-bound VDR directly downregulated the EMT inducer SNAI2, differentiating highly metastatic from low metastatic subtypes and 1,25(OH)2D sensitivity. Moreover, epigenome-wide motif and putative target gene analysis revealed the VDR’s integration with NMD tumorigenic and immunogenic ...
Source: Frontiers in Oncology - May 9, 2023 Category: Cancer & Oncology Source Type: research
Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines
CONCLUSION: Lipofectamine 2000 was the least toxic transfection reagent in osteo- and chondrosarcoma. Successful siRNA-induced MDR1 mRNA silencing of over 80% was achieved.PMID:37148005 | DOI:10.4103/jcrt.JCRT_565_19
Source: Cell Research - May 6, 2023 Category: Cytology Authors: Sarah S Freund Michael M Bendtsen Akmal Safwat Peter H Joergensen Source Type: research
ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Transl Res. 2023 Apr 28:S1931-5244(23)00072-5. doi: 10.1016/j.trsl.2023.04.005. Online ahead of print.ABSTRACTAberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-medi...
Source: Translational Research : the journal of laboratory and clinical medicine - April 30, 2023 Category: Laboratory Medicine Authors: Xueying An Wenshu Wu Lin Yang Jian Dong Bin Liu Junxia Guo Jianmei Chen Baosheng Guo Wangsen Cao Qing Jiang Source Type: research
